CoChat

Pulmonary fibrosis: a cellular overreaction or a failure of communication?

Open access
Sheppard, Dean · 2001 · Journal of Clinical Investigation
Cited by 70

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Historically, idiopathic pulmonary fibrosis was thought to be a deleterious consequence of persistent lung inflammation that followed an unknown insult. However, the growing recognition that foci of proliferating fibroblasts are more prominent than evidence of inflammation in lung tissue (1), as well as the lack of efficacy of anti-inflammatory drugs in the majority of affected patients, has led to a focus on the fibrotic pathway itself (2).At first blush, the article by Kolb et al. in this issue of the JCI (3) might suggest that we may have discounted inflammation too hastily. The authors show that treatment of rats with a single dose of a recombinant adenovirus encoding the cytokine IL-1β, a central regulator of acute inflammation (4), leads to a progressive form of pulmonary fibrosis that continues over at least 60 days. Importantly, this progression is not due to any persistent effects of IL-1β itself, since, as expected with adenovirus infection, IL-1β expression is only increased transiently, returning to near base-line values by 14 days after infection. In contrast, pulmonary fibrosis (as determined by increases in lung hydroxyproline content) is not apparent until day 21 and dramatically increases thereafter. Thus, IL-1β can be added to a short list of agents, including the cytotoxic drug bleomycin (5), ligands of the Fas death receptor (6), and the cytokine TGF-β1 (7), that can bypass the normal repair process and initiate a self-perpetuating cycle of pulmonary fibrosis.Should the article by Kolb et al. (3) rekindle enthusiasm for focusing on acute inflammation in our efforts to better understand the mechanisms underlying diseases characterized by progressive pulmonary fibrosis? I think not. Although severe acute inflammation occurred in response to IL-1β, the inflammatory response had resolved by the time fibrosis became apparent and was thus not required for subsequent progression. Although the mechanisms by which IL-1β leads to progressive fibrosis were not clearly defined, the presence of progressive lung fibrosis well after IL-1β concentrations had returned to base line suggests that transient overexpression of this cytokine resulted in dysregulation of processes needed for normal lung repair.There are at least two possible explanations for the findings in this study. The first is that IL-1β itself somehow reprograms one or more lung cell to continuously produce increased concentrations of profibrotic cytokines, especially TGF-β1. This is an attractive hypothesis, since several lines of evidence suggest that TGF-β1 is a central regulator of pulmonary fibrosis (8, 9). Indeed, since substantial TGF-β1 is present in latent form in the lungs of healthy adults, pulmonary fibrosis can result from local activation of the latent cytokine (10) (e.g., through the action of the epithelial integrin αvβ6 [ref. 11]), even in the absence of any increase in TGF-β protein expression.An alternative explanation might be derived from examination of normal lung development. The mammalian lung depends on a spatially complex and structurally fragile architecture to perform its essential function of gas exchange. Amazingly, this exquisitely precise structure can reform in adults following formidable injuries by microorganisms, environmental insults, or blood-borne toxins. It is thus apparent that the lung microenvironment has a robust capacity to recapitulate at least some of the developmental programs that generated this complex structure in the first place. How then, are components of this developmental process reactivated to effectively repair severely injured lungs of patients recovering from overwhelming bacterial pneumonia or the acute lung injury of sepsis? What fails in the less frequent cases when progressive, fatal lung fibrosis ensues? Herein lie the central issues facing physicians and scientists trying to understand pulmonary fibrosis and to improve methods for treating affected patients.Although many of the details of normal lung development remain to be fully elucidated, it is quite clear that a central feature is a network of reciprocal inductive and inhibitory signals involving at least mesenchymal cells, pulmonary epithelial cells, and components of the ECM (Figure ​(Figure1)1) (12). During development, tight spatial and temporal regulation of this cellular conversation is essential, and the balance of inputs from mesenchyme and epithelium is crucial. Thus, either overexpression or inhibition of some of the critical products of either cell type — e.g., members of the TGF-β (13), Hedgehog (14), or FGF families (15) — can dramatically disrupt lung development. In this context, the role of IL-1β in the model described by Kolb et al. (3) could be principally to induce sufficiently severe acute inflammation to cause complete or disproportionate loss of epithelial or mesenchymal cells or of the ECM proteins required to induce normal repair. Indeed, with the exception of TGF-β1, each of the stimuli known t

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci13318

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 70

Metadata

Authors
Sheppard, D.
Venue
Journal of Clinical Investigation
Published
2001-06-15
Volume
107
Issue
12
Pages
1501-1502
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2026046897
Cited by
70
References
1
FWCI
7.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pulmonary fibrosis: a cellular overreaction or a failure of communication? https://app.cochat.ai/papers/10.1172/jci13318
The paper
Sheppard, D. (2001). Pulmonary fibrosis: a cellular overreaction or a failure of communication? Journal of Clinical Investigation. https://doi.org/10.1172/jci13318

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.